{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibrbxrlied7uczzcqvebsuh7ikr3wppfxl2llg3auosnpeebaiwii",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mk2idmzjxp72"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreie5hfmm5a4lq3qoqb24o6tlacywkpytbeuctdfsir4nlp4jfsqvz4"
    },
    "mimeType": "image/jpeg",
    "size": 79152
  },
  "path": "/2026/04/21/aacr-2026-pancreatic-cancer-oral-cancer-wildfires-nci-director/?utm_campaign=rss",
  "publishedAt": "2026-04-21T22:18:45.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Health",
    "Pharma",
    "AACR",
    "biotech",
    "Cancer",
    "drug development",
    "environmental health",
    "NIH",
    "pharma",
    "STAT+"
  ],
  "textContent": "At AACR, Revolution Medicines presented more eye-catching data about its KRAS-targeting treatment, and Anthony Letai declared the state of cancer research steady.",
  "title": "STAT+: At AACR, more strong results for Revolution Medicine’s KRAS drug, plus assurance from NCI’s director",
  "updatedAt": "2026-04-21T22:21:54.000Z"
}